iloperidone: clinical trials recruiting now
3
Recruiting trials
5
Conditions studied
22
US states with sites
1
Countries
FDA drug label
- FDA-approved
- Yes. iloperidone appears in the FDA drug-label database. Marketed as FANAPT.
- Drug class
- Atypical Antipsychotic (FDA established pharmacologic class)
- Boxed warning
- The FDA label for iloperidone carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . FANAPT is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 , 14.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. ( 1 , 14.2 )
Phase breakdown
Phase 2 1
Phase 3 1
Phase 4 1
Conditions being studied
| Condition | Trials |
|---|---|
| Schizophrenia | 2 |
| Bipolar I Disorder | 1 |
| Bipolar disorder | 1 |
| Hypertension | 1 |
| Uncontrolled Hypertension | 1 |
Recruiting trials involving iloperidone
- Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
- Randomized Withdrawal Study in Patients With Schizophrenia
- Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Common questions
Is iloperidone FDA-approved?
Yes, marketed as FANAPT. Its FDA label carries a boxed warning.
How many recruiting trials involve iloperidone?
3 recruiting trials across 5 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.